Canada markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
49.15+0.57 (+1.17%)
At close: 04:03PM EDT
49.14 -0.01 (-0.02%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close48.58
Open48.84
Bid49.05 x 800
Ask49.13 x 1400
Day's Range48.73 - 49.44
52 Week Range40.94 - 61.71
Volume14,739,354
Avg. Volume20,234,166
Market Cap275.847B
Beta (5Y Monthly)0.62
PE Ratio (TTM)9.69
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.60 (3.25%)
Ex-Dividend DateJul 28, 2022
1y Target EstN/A
  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    NEW YORK, August 19, 2022--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer, President, Worldwide Research, Development and Medical, at the Handelsbanken Life Science Innovation Day 2022 on Wednesday, August 24, 2022 at 4:30 p.m. CEST (10:30 a.m. EDT).

  • Business Wire

    Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants

    NEW YORK, August 12, 2022--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.

  • Business Wire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.